These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 24395350)
41. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma. Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115 [TBL] [Abstract][Full Text] [Related]
42. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611 [TBL] [Abstract][Full Text] [Related]
43. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084 [TBL] [Abstract][Full Text] [Related]
44. Is there pseudoprogression in secondary glioblastomas? Juratli TA; Engellandt K; Lautenschlaeger T; Geiger KD; von Kummer R; Cerhova J; Chakravarti A; Krex D; Schackert G Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1094-9. PubMed ID: 24267971 [TBL] [Abstract][Full Text] [Related]
45. Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study. Annavarapu S; Gogate A; Pham T; Davies K; Singh P; Robert N CNS Oncol; 2021 Sep; 10(3):CNS76. PubMed ID: 34378977 [TBL] [Abstract][Full Text] [Related]
46. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. Franceschi E; Depenni R; Paccapelo A; Ermani M; Faedi M; Sturiale C; Michiara M; Servadei F; Pavesi G; Urbini B; Pisanello A; Crisi G; Cavallo MA; Dazzi C; Biasini C; Bertolini F; Mucciarini C; Pasini G; Baruzzi A; Brandes AA; J Neurooncol; 2016 May; 128(1):157-162. PubMed ID: 26943851 [TBL] [Abstract][Full Text] [Related]
47. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). Lombardi G; Pace A; Pasqualetti F; Rizzato S; Faedi M; Anghileri E; Nicolotto E; Bazzoli E; Bellu L; Villani V; Fabi A; Ferrazza P; Gurrieri L; Dall'Agata M; Eoli M; Della Puppa A; Pambuku A; D'Avella D; Berti F; Rudà R; Zagonel V J Neurooncol; 2015 Nov; 125(2):359-67. PubMed ID: 26423801 [TBL] [Abstract][Full Text] [Related]
48. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients? Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743 [TBL] [Abstract][Full Text] [Related]
49. MGMT gene silencing and benefit from temozolomide in glioblastoma. Hegi ME; Diserens AC; Gorlia T; Hamou MF; de Tribolet N; Weller M; Kros JM; Hainfellner JA; Mason W; Mariani L; Bromberg JE; Hau P; Mirimanoff RO; Cairncross JG; Janzer RC; Stupp R N Engl J Med; 2005 Mar; 352(10):997-1003. PubMed ID: 15758010 [TBL] [Abstract][Full Text] [Related]
51. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. Gilbert MR; Wang M; Aldape KD; Stupp R; Hegi ME; Jaeckle KA; Armstrong TS; Wefel JS; Won M; Blumenthal DT; Mahajan A; Schultz CJ; Erridge S; Baumert B; Hopkins KI; Tzuk-Shina T; Brown PD; Chakravarti A; Curran WJ; Mehta MP J Clin Oncol; 2013 Nov; 31(32):4085-91. PubMed ID: 24101040 [TBL] [Abstract][Full Text] [Related]
52. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide. Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009 [TBL] [Abstract][Full Text] [Related]
53. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196 [TBL] [Abstract][Full Text] [Related]
54. MGMT promoter methylation in plasma of glioma patients receiving temozolomide. Fiano V; Trevisan M; Trevisan E; Senetta R; Castiglione A; Sacerdote C; Gillio-Tos A; De Marco L; Grasso C; Magistrello M; Tondat F; Rudà R; Cassoni P; Soffietti R; Merletti F J Neurooncol; 2014 Apr; 117(2):347-57. PubMed ID: 24519517 [TBL] [Abstract][Full Text] [Related]
56. Radiation and concomitant chemotherapy for patients with glioblastoma multiforme. Villà S; Balañà C; Comas S Chin J Cancer; 2014 Jan; 33(1):25-31. PubMed ID: 24325790 [TBL] [Abstract][Full Text] [Related]
57. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165 [TBL] [Abstract][Full Text] [Related]
58. Treatment considerations for MGMT-unmethylated glioblastoma. Taylor JW; Schiff D Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859 [TBL] [Abstract][Full Text] [Related]
59. Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. Makino K; Nakamura H; Hide T; Kuratsu J J Neurooncol; 2012 Jan; 106(1):155-60. PubMed ID: 21720808 [TBL] [Abstract][Full Text] [Related]
60. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. Paravati AJ; Heron DE; Landsittel D; Flickinger JC; Mintz A; Chen YF; Huq MS J Neurooncol; 2011 Aug; 104(1):339-49. PubMed ID: 21181233 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]